Current evidence supports inhibiting mortalin to prevent or overcome cancer resistance to inhibitors of the raf/MAPK/MEK/ERK signaling pathway [114,115] and to paclitaxel [116] and to complement inhibition of mutant p53 [78]. The gene discussed is TP53; the disease is cancer.